Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2023

	*September 30,*		*December 31,*
	*2023*		*2022*
Compensation expense	$	8,735	$	3,015
Research and development fees		1,971		5,758
Accrued accounts payable		1,348		1,245
Other current liabilities		575		483
Accrued license obligations		135		245
Total	$	12,764	$	10,746